Vir Biotechnology (NASDAQ:VIR) Major Shareholder Endurance (Cayman) Ltd Svf Sells 235,971 Shares of Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) major shareholder Endurance (Cayman) Ltd Svf sold 235,971 shares of the business’s stock in a transaction that occurred on Tuesday, November 25th. The stock was sold at an average price of $6.38, for a total value of $1,505,494.98. Following the sale, the insider owned 14,110,209 shares of the company’s stock, valued at approximately $90,023,133.42. This represents a 1.64% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Endurance (Cayman) Ltd Svf also recently made the following trade(s):

• On Monday, November 24th, Endurance (Cayman) Ltd Svf sold 227,803 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.15, for a total transaction of $1,400,988.45.
• On Wednesday, October 29th, Endurance (Cayman) Ltd Svf sold 100 shares of Vir Biotechnology stock. The stock was sold at an average price of $6.49, for a total transaction of $649.00.
• On Tuesday, October 28th, Endurance (Cayman) Ltd Svf sold 24,453 shares of Vir Biotechnology stock. The stock was sold at an average price of $6.50, for a total transaction of $158,944.50.
• On Monday, October 27th, Endurance (Cayman) Ltd Svf sold 66,403 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.05, for a total value of $401,738.15.
• On Friday, October 24th, Endurance (Cayman) Ltd Svf sold 46,696 shares of Vir Biotechnology stock. The stock was sold at an average price of $5.96, for a total value of $278,308.16.
• On Thursday, October 23rd, Endurance (Cayman) Ltd Svf sold 154,383 shares of Vir Biotechnology stock. The shares were sold at an average price of $5.99, for a total value of $924,754.17.
• On Wednesday, October 22nd, Endurance (Cayman) Ltd Svf sold 144,266 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.15, for a total value of $887,235.90.
• On Tuesday, October 21st, Endurance (Cayman) Ltd Svf sold 109,675 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.30, for a total value of $690,952.50.
• On Monday, October 20th, Endurance (Cayman) Ltd Svf sold 220,535 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.20, for a total transaction of $1,367,317.00.
• On Thursday, October 16th, Endurance (Cayman) Ltd Svf sold 12,844 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.10, for a total value of $78,348.40.

Vir Biotechnology Trading Down 0.8%

VIR opened at $6.39 on Thursday. The company’s 50 day moving average is $5.71 and its 200-day moving average is $5.28. The company has a market cap of $888.98 million, a P/E ratio of -1.77 and a beta of 1.27. Vir Biotechnology, Inc. has a 1-year low of $4.16 and a 1-year high of $14.45.

Vir Biotechnology (NASDAQ:VIR) last posted its earnings results on Wednesday, November 5th. The company reported ($1.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.47). Vir Biotechnology had a negative return on equity of 50.76% and a negative net margin of 2,963.54%.The company had revenue of $0.24 million for the quarter, compared to the consensus estimate of $1.98 million. During the same period in the previous year, the firm posted ($1.56) EPS. The business’s quarterly revenue was up .8% compared to the same quarter last year. On average, equities analysts forecast that Vir Biotechnology, Inc. will post -3.92 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. Raymond James Financial Inc. bought a new stake in Vir Biotechnology during the second quarter worth $35,000. Federated Hermes Inc. raised its holdings in shares of Vir Biotechnology by 153.8% in the 3rd quarter. Federated Hermes Inc. now owns 8,085 shares of the company’s stock worth $46,000 after purchasing an additional 4,899 shares during the period. Apollon Wealth Management LLC bought a new position in Vir Biotechnology during the second quarter valued at $50,000. PNC Financial Services Group Inc. increased its position in Vir Biotechnology by 26.2% in the first quarter. PNC Financial Services Group Inc. now owns 10,459 shares of the company’s stock worth $68,000 after buying an additional 2,171 shares during the last quarter. Finally, FORA Capital LLC bought a new position in shares of Vir Biotechnology during the 1st quarter worth $70,000. 65.32% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

VIR has been the topic of a number of recent research reports. Evercore ISI assumed coverage on Vir Biotechnology in a research note on Wednesday, September 3rd. They set an “outperform” rating and a $12.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price target on shares of Vir Biotechnology in a research note on Monday, September 15th. Weiss Ratings restated a “sell (e+)” rating on shares of Vir Biotechnology in a report on Monday. Finally, Bank of America raised Vir Biotechnology from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $12.00 to $14.00 in a report on Wednesday, August 27th. Nine investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $17.30.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).